Lyka Labs Q1 FY27: consolidated PAT doubles YoY to ₹2.05 Cr as revenue rises 28%

Lyka Labs' consolidated revenue for the quarter ended 30 June 2026 rose 28.1% YoY to ₹42.31 Cr from ₹33.03 Cr, while consolidated PAT more than doubled YoY to ₹2.05 Cr from ₹1.00 Cr — a print that also reverses the ₹8.07 Cr consolidated loss booked in the March-2026 quarter. PBT grew a more modest 44% YoY to ₹1.95 Cr; the extra lift to PAT came from a ₹0.10 Cr deferred-tax credit versus a ₹0.05 Cr tax charge a year ago, so the bottom-line gain overstates the operating improvement. NPM (PAT/total income) rose to 4.79% from 2.96% YoY, but OPM was essentially flat at 10.75% against 11.16% a year ago — cost ratios for materials, employee expense and other overheads moved only marginally — making this more a tax-and-base-effect story than a margin-expansion one. Standalone tracks closely (revenue ₹42.31 Cr, PAT ₹2.10 Cr, EPS ₹0.58 vs ₹0.22 YoY); the ₹0.05 Cr gap to consolidated PAT is the subsidiary Lyka BDR International's own quarterly loss. On the same day, the board also approved 100% divestment of Lyka BDR International — a subsidiary that contributed 8% of FY26 consolidated income (₹10.55 Cr) and carries a negative net worth of ₹4.49 Cr — with sale terms, buyer and consideration still to be finalised and delegated to the Audit Committee. Separately, the NCLT-sanctioned merger of Lyka Export Limited into Lyka Labs (order dated 16 March 2026) is now reflected in restated prior-period figures under Ind AS 103. There is no formal management guidance on record for this company, and a web search for Q1 FY27 previews/estimates turned up no analyst or brokerage coverage for this micro-cap, so both vs-guidance and vs-street are unknown; the filing itself carries no separate management commentary beyond the standard board-outcome letter. The subsidiary sale terms and whether the deferred-tax credit that flattered this quarter's PAT persists are the two items likely to matter more to the trend than this quarter's headline number.